Denali Therapeutics Inc is a biopharmaceutical company focused on developing innovative therapies for neurodegenerative diseases
The company is dedicated to advancing scientific research and applying cutting-edge technologies to create treatments targeting conditions such as Alzheimer’s disease and Parkinson’s disease. By leveraging its expertise in neurology and drug discovery, Denali aims to understand the underlying mechanisms of these complex disorders and develop effective therapeutic options that can significantly improve patient outcomes and quality of life.
Denali Therapeutics' ALS drug DNL343 failed to show efficacy, leading to the discontinuation of the trial extension. Analysts now focus on its Hunter syndrome drug.
Denali Therapeutics showcases its BBB platform at J.P. Morgan Conference, highlighting DNL310's Hunter syndrome progress and plans for commercialization.
Denali's DNL343 missed efficacy goals in the HEALEY ALS trial but was well-tolerated. Analysts await detailed biomarker data and subgroup analyses in 2025.
William Blair starts coverage on Denali Therapeutics with an Outperform rating, citing its transport vehicle platform and promising therapies for neurodegenerative diseases.
Denali Therapeutics shares are moving lower in Thursday's after-hours session after the company announced that its Phase 2 study of oditrasertib was discontinued.
It’s hard to focus on biotech stocks right now because there are many distractions. The Fed and the rate cuts, AI and semiconductor stocks and geopolitical turmoil seemingly worse than ever.
Insights from Wedbush analysts about the clinical effectiveness of REGENXBIO's RGX-202, market potential, and challenges posed by competitors like Sarepta Therapeutics and Pfizer.
